SVRA logo

Savara Inc. Stock Price

NasdaqGS:SVRA Community·US$1.4b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author

SVRA Share Price Performance

US$5.27
2.26 (75.08%)
US$5.27
2.26 (75.08%)
Price US$5.27

SVRA Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

High growth potential with excellent balance sheet.

2 Risks
1 Reward

Savara Inc. Key Details

US$0

Revenue

US$86.8m

Cost of Revenue

-US$86.8m

Gross Profit

US$52.5m

Other Expenses

-US$139.3m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.55
0%
0%
20.4%
View Full Analysis

About SVRA

Founded
2007
Employees
70
CEO
Matthew Pauls
WebsiteView website
www.savarapharma.com

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

Recent SVRA News & Updates

Seeking Alpha Aug 05

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

Summary Savara Inc. (SVRA) is revisited, focusing on its APAP BLA filing progress. The article assesses SVRA's clinical and regulatory milestones as key investment drivers. Upcoming APAP BLA PDUFA is highlighted as a pivotal near-term catalyst. Investment thesis centers on SVRA's execution and regulatory pathway for APAP. Read the full article on Seeking Alpha

Recent updates

No updates